Literature DB >> 11915023

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.

Liang Qiao1, Adly Yacoub, Elaine Studer, Seema Gupta, Xin Yan Pei, Steven Grant, Philip B Hylemon, Paul Dent.   

Abstract

The mechanisms by which bile acids induce apoptosis in hepatocytes and the signaling pathways involved in the control of cell death are not understood fully. Here, we examined the impact of mitogen-activated protein kinase (MAPK) and phosphatidyl inositol 3-kinase (PI3K) signaling on the survival of primary hepatocytes exposed to bile acids. Treatment of hepatocytes with deoxycholic acid (DCA), chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA) caused sustained MAPK activation that was dependent on activation of the epidermal growth factor receptor (EGFR). Activation of MAPK was partially blocked by inhibitors of PI3K. Inhibition of DCA-, CDCA-, and UDCA-stimulated MAPK activation resulted in approximately 20%, approximately 35%, and approximately 55% apoptosis, respectively. The potentiation of DCA- and CDCA-induced apoptosis by MEK1/2 inhibitors correlated with cleavage of procaspase 3, which was blocked by inhibitors of caspase 8 (ile-Glu-Thr-Asp-p-nitroanilide [IETD]) and caspase 3 (DEVD). In contrast, the potentiation of UDCA-induced apoptosis weakly correlated with procaspase 3 cleavage, yet this effect was also blocked by IETD and DEVD. Incubation of hepatocytes with the serine protease inhibitor AEBSF reduced the death response of cells treated with UDCA and MEK1/2 inhibitor to that observed for DCA and MEK1/2 inhibitor. The apoptotic response was FAS receptor- and neutral sphingomyelinase-dependent and independent of FAS ligand expression, and neither chelation of intracellular and extracellular Ca(2+) nor down-regulation of PKC expression altered the apoptotic effects of bile acids. In conclusion, bile acid apoptosis is dependent on the production of ceramide and is counteracted by activation of the MAPK and PI3K pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11915023     DOI: 10.1053/jhep.2002.32533

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.

Authors:  Elaine Studer; Xiqiao Zhou; Renping Zhao; Yun Wang; Kazuaki Takabe; Masayuki Nagahashi; William M Pandak; Paul Dent; Sarah Spiegel; Ruihua Shi; Weiren Xu; Xuyuan Liu; Pat Bohdan; Luyong Zhang; Huiping Zhou; Phillip B Hylemon
Journal:  Hepatology       Date:  2011-11-30       Impact factor: 17.425

Review 2.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

3.  Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.

Authors:  Marco Marzioni; Heather Francis; Antonio Benedetti; Yoshiyuki Ueno; Giammarco Fava; Juliet Venter; Ramona Reichenbach; Maria Grazia Mancino; Ryun Summers; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 4.  Ursodeoxycholic acid in chronic hepatitis C.

Authors:  Raoul Poupon; Lawrence Serfaty
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

5.  Activation of MEK 1/2 and p42/44 MAPK by angiotensin II in hepatocyte nucleus and their potentiation by ethanol.

Authors:  Annayya R Aroor; Youn Ju Lee; Shivendra D Shukla
Journal:  Alcohol       Date:  2009-06       Impact factor: 2.405

6.  Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Andrew D Patterson; Joo-Youn Cho; Kristopher W Krausz; Frank J Gonzalez
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 7.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

8.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

9.  Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats.

Authors:  Cecilia M P Rodrigues; Susana Sola; Zhenhong Nan; Rui E Castro; Paulo S Ribeiro; Walter C Low; Clifford J Steer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

10.  Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway.

Authors:  Susana Solá; Rui E Castro; Pedro A Laires; Clifford J Steer; Cecília M P Rodrigues
Journal:  Mol Med       Date:  2003 Sep-Dec       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.